| Date | Title | Description |
| 26.03.2025 | Peijia Medical Announces 2024 Annual Results | HONG KONG, March 26, 2025 /PRNewswire/ -- Peijia Medical (9996.HK), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the year ende... |
| 29.08.2024 | Peijia Medical's Strong Growth in 2024: A Deep Dive into Interim Results | Peijia Medical, a prominent player in China's medical device market, has unveiled its interim results for the first half of 2024. The numbers tell a compelling story of growth, resilience, and strategic execution. With a sharp focus on tran... |
| 26.08.2024 | Peijia Medical Announces 2024 Interim Results | HONG KONG, Aug. 26, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six month... |
| 26.08.2024 | Peijia Medical Announces 2024 Interim Results | HONG KONG, Aug. 26, 2024 /PRNewswire/ -- Peijia Medical (HKG:9996), a leading Chinese domestic player in the high-growth transcatheter valve therapeutics and neurovascular interventions markets, announced financial results for the six month... |
| 25.07.2024 | Peijia Medical's Licensing Partner, JenaValve Technology, Inc., is Expected to be Acquired by Edwards Lifesciences | Peijia to maintain exclusive rights in Greater China to commercialize JenaValve's Trilogy Transcatheter Heart Valve (THV) System
SUZHOU, China, July 25, 2024 /PRNewswire/ -- Peijia Medical Limited (Peijia, (9996.HK)), a leading Chinese dome... |
| 04.03.2024 | Structural Heart Devices Market Surges as Aging Population Spurs Cardiovascular Health Concerns | A structural heart disease is a non-coronary defect of the heart, thus not affecting the blood vessels in the heart.
PORTLAND, OREGON, UNITED STATES, March 4, 2024 /EINPresswire.com/ -- According to a new report published by Allied Market R... |
| 27.10.2023 | JenaValve Announces Late-Breaking Data from the ALIGN-AR Pivotal Trial Meeting Safety and Efficacy Endpoints | The trial met prespecified non-inferiority criteria for its primary safety endpoint and primary efficacy endpoint. Outcomes were presented by Dr. Vinod Thourani (Piedmont Heart Institute, Atlanta, GA) during the opening Late-Breaking Clinic... |
| 24.10.2023 |
Slow and steady wins the race: JenaValve aims to offer new option for aortic regurgitation patients | The Munich-based startup JenaValve is a bit like the tortoise, with a slow and steady approach to transcatheter aortic valve replacement (TAVR) device development.
At the Transcatheter Cardiovascular Therapeutics (TCT) conference today, Dr.... |
| 01.09.2022 | JenaValve Raises $100M in Series C Funding | JenaValve, an Irvine, CA-based developer and manufacturer of differentiated transcatheter aortic valve replacement (TAVR) systems, raised $100M in Series C funding.
The round was led by Bain Capital Life Sciences with participation from exi... |
| 31.08.2022 | JenaValve nabs $100M to clear a path toward FDA approval of dual-use TAVR system | In a fitting move for the maker of heart-valve-opening technology, California-based startup JenaValve has taken another step toward opening up the device’s pathway to the U.S. commercial market.
The company announced Wednesday that it recen... |
| 10.02.2020 |
JenaValve Finds $50M Funding
| Irvine-based JenaValve Technology, which develops aortic valve replacements, said last week that it has raised $50M in a financing round. The funding was led by Bain Capital Life Sciences, and also included existing investors Andera Partner... |
| 10.02.2020 | Daily funding roundup - February 10th, 2020 | Kintaba raised $2.25; Midnite landed $2.5M; SteeleEye secured $10M; Boulder Care picks up $10.5M
Kintaba: Kintaba is an incident response startup created by former product leads for Facebook's first major enterprise offering. Kintaba has ra... |
| 07.02.2020 | TAVR developer JenaValve nets $50M from Bain Capital Life Sciences | Heart valve maker JenaValve Technology has raised $50 million in new venture capital funding, not long after receiving a breakthrough device designation from the FDA for its transcatheter aortic valve replacement (TAVR) system.
The equity f... |
| 07.02.2020 | TAVR developer JenaValve nets $50M from Bain Capital Life Sciences | Heart valve maker JenaValve Technology has raised $50 million in new venture capital funding, not long after receiving a breakthrough device designation from the FDA for its transcatheter aortic valve replacement (TAVR) system.
Sponsored by... |
| 05.02.2020 | JenaValve Technology Closes $50 Million Financing | IRVINE, Calif.--(BUSINESS WIRE)--JenaValve Technology, Inc., developer and manufacturer of the JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System for the treatment of aortic valve disease, announces that it has raise... |
| 05.02.2020 | JenaValve Technology Closes $50M Financing |
IRVINE, CA, JenaValve Technology has raised $50 million in an equity financing led by Bain Capital Life Sciences.
>> Click here for more funding data on JenaValve
>> To export JenaValve funding data to PDF and Excel, click h... |
| 05.02.2020 | JenaValve Technology Raises $50 Million And Andrew Hack Joins Board | JenaValve Technology, a developer and manufacturer of the JenaValve Pericardial Transcatheter Aortic Valve Replacement (TAVR) System, has raised $50 million
JenaValve Technology — a developer and manufacturer of the JenaValve Pericardial Tr... |
| 18.08.2016 | Aortic stenosis patients with moderate risk to open-heart surgery can now choose TAVR instead | One such company is Edwards Lifesciences that announced Thursday that the Food and Drug Administration has expanded the label indication for its Sapien 3 TAVR valve to include patients who have intermediate risk for open-heart procedures.
W... |
| 07.08.2015 | JenaValve’s Series C swells to nearly $100M for its TAVI implants that treat cardiovascular stenosis | The company already has a CE mark for two indications — aortic valve stenosis and insufficiency — and is looking for more, including acceptance in the U.S. market. Indeed, the funding will go toward a series of clinical trials that will pre... |
| 07.08.2015 | Daily funding roundup - August 7, 2015 | JenaValve completed $26.5M; Dinner Lab raised $7M: Lemonade Lab secured $5.8M
Rebagg, a frictionless luxury resale service, announced the close of a $4.0 Million Seed round of funding led by General Catalyst. Metamorphic Ventures, Crosslink... |
| 07.08.2015 | JenaValve Technology Completes $26.5M Series C Financing | JenaValve Technology, Inc., a Munich, Germany and Irvine, California-based developer, manufacturer and marketer of next-generation transcatheter aortic valve repair (TAVR) systems for the treatment of aortic valve disease, completed a $26.5... |
| 07.08.2015 |
JenaValve Gets $26.5M for Aorta Repair Device
| Irvine-based JenaValve Technology, which is developing transcatheter aortic valve repair (TAVR) systems for the treatment of aortic valve disease, said this morning that it has raised $26.5M in a Series C funding round. The funding was led ... |
| 10.02.2015 | JenaValve taps medtech vet Keltjens for interim CEO | Personnel Moves | JenaValve tapped a medtech veteran with a string of successful exits behind him as interim chairman & CEO, replacing another medical device vet, David Drachman, after just 7 months.
Drachman, who spent 10 years in the corner office at A... |
| 08.04.2014 | JenaValve Technology Raises Additional $10M in Series C Venture Funding | JenaValve Technology, Inc., a Wilmington, DE- and Munich, Germany-based developer of transcatheter aortic valve implantation systems for aortic valve disease, raised an additional $10m in Series C venture funding.
Backers included new inves... |
| 08.04.2014 | JenaValve Expands Series C |
MUNICH, GERMANY, Developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today that it has secured an expansion to its Series C venture round.
&g... |
| 23.07.2013 | JenaValve Technology Grabs $62.5M Series C |
MUNICH, GERMANY, Privately-held developer, manufacturer and marketer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, announced today that it has raised $62.5 million in a Series C ventu... |
| 23.07.2013 | JenaValve Technology Raises $62.5M in Series C Venture Round | JenaValve Technology, Inc., a developer of transcatheter aortic valve implantation (TAVI) systems for the treatment of aortic valve disease, raised $62.5m in a Series C venture round.
Backers included Gimv (GIMB.EN), Beijing-based Legend Ca... |
| - | Aortic stenosis patients with moderate risk to open-heart surgery can now choose TAVR instead | Transcatheter aortic valve replacement (TAVR) has been steadily gaining ground as studies have shown its superiority over invasive, open-heart surgery for patients suffering from aortic stenosis.
The cohort of patients who first got access ... |
| - | JenaValve’s Series C swells to nearly $100M for its TAVI implants that treat cardiovascular stenosis | JenaValve Technology just added another $26.5 million to its expanding Series C round, which looks to have swelled to near $100 million.
The financing round was led by RMM and Valiance, and included Atlas Ventures, Edmond de Rothschild Inve... |
